Maverick Capital’s Medicines Co MDCO Stock Holding History

Maverick Capital’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,176,487	Closed	-$185M	–	563
2019 Q4	$185M	Sell	2,176,487 -1,707,552	-44%	-$114M	2.69%	12
2019 Q3	$194M	Buy	3,884,039 +16,956	+0.4%	+$676K	2.85%	12
2019 Q2	$141M	Buy	3,867,083 +52,731	+1%	+$1.72M	2.04%	15
2019 Q1	$107M	Buy	3,814,352 +299,375	+9%	+$7.06M	1.41%	20
2018 Q4	$67.3M	Buy	3,514,977 +2,150,140	+158%	+$50M	0.99%	28
2018 Q3	$40.8M	Buy	1,364,837 +159,556	+13%	+$6.01M	0.51%	35
2018 Q2	$44.2M	Buy	1,205,281 +299,030	+33%	+$9.72M	0.52%	34
2018 Q1	$29.9M	Buy	+906,251	New	+$28.3M	0.39%	35

Other funds holding MDCO

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Maverick Capital's MDCO Position: Q1 2020 in Review

Maverick Capital sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 2,176,487 shares — an estimated $185M sold.

Maverick Capital first reported a position in MDCO in Q1 2018 and held it in 8 quarters. The position peaked at $194M in Q3 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

Maverick Capital reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
Maverick Capital sold 2,176,487 Medicines Co shares in Q1 2020, an estimated $185M.
Maverick Capital first reported a position in Medicines Co in Q1 2018 and held it in 8 quarters.
Maverick Capital's Medicines Co position peaked at $194M in Q3 2019.
1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Maverick Capital's 13F filing for Q1 2020, filed 15 May 2020.